Get started
Author

M. Rudwaleit

Observed name: Rudwaleit, M.
OpenAlex ID: A5034040974
Pos0939 Bimekizumab in Patients With Active Non-radiographic Axial Spondyloarthritis: 24-week Efficacy & Safety From Be Mobile 1, a Phase 3, Multicentre, Randomised, Placebo‑controlled Study
2022 · A. Deodhar, D. Van der Heijde, et al. · Annals of the Rheumatic Diseases · 5
PDF
Pos0773 Low Uveitis Rates in Patients With Axial Spondyloarthritis or Psoriatic Arthritis Treated With Bimekizumab: Long-term Results From Phase 2b/3 Trials
2025 · I. van der Horst-Bruinsma, M. Brown, et al. · Annals of the Rheumatic Diseases · 2
Pos0785 Efficacy of Ixekizumab in Radiographic Axial Spondyloarthritis Patients With Normal and Elevated Crp: a Pooled Analysis of Phase Iii Clinical Trials
2025 · R. Sengupta, X. Baraliakos, et al. · Annals of the Rheumatic Diseases · 1
Pos0867 Machine Learning Model Outperforms Conventional Logistic Regression in Predicting Spinal Radiographic Progression Over 2-year Intervals in Axial Spondyloarthritis
2025 · I. Redeker, M. Torgutalp, et al. · Annals of the Rheumatic Diseases
Pos0743 Optimizing Referral to Rheumatology – a New Strategy to Prevent Referral of Patients With Low Likelihood of an Inflammatory Rheumatic Disease
2024 · M.H. Röchter, S. Schmiegel, et al. · Annals of the Rheumatic Diseases
Pos0941 Long-term Clinical Outcomes of Certolizumab Pegol Treatment in Patients With Active Non‑radiographic Axial Spondyloarthritis Stratified by Baseline Mri and C-reactive Protein Status
2022 · P. Robinson, W.P. Maksymowych, et al. · Annals of the Rheumatic Diseases
PDF
J Exp Med
2008 · Niesner, U., Albrecht, I., et al. · MPG.PuRe (Max Planck Society)
Works count: 7
Citation count: 8
H-index: 2
I10-index:
Year
Topic
Type